Novo president and chief executive officer Mike Doustdar talked about Ozempic, Wegovy, new GLP-1 medications, weight loss and obesity and the company's new rebrand
Novo CEO Doustdar On What’s New For Ozempic, Wegovy, GLP-1s, Obesity

Novo president and chief executive officer Mike Doustdar talked about Ozempic, Wegovy, new GLP-1 medications, weight loss and obesity and the company's new rebrand
Key Takeaways
- Novo CEO Doustdar On What’s New For Ozempic, Wegovy, GLP-1s, Obesity.
Read Complete Original Article
Published originally on Forbes Business





